Company: BLLN
Filing Date: 2025-10-17
Form Type: S-1/A
Source: 0001193125-25-242632
Chunk: 387

Company: BillionToOne, Inc.
Filing Date: 2025-10-17
Form: S-1/A
Chunk 387
---
:|:----|:-----|------:|
| Cash payments for interest                                                                     |     | $                |  1,656 |     | $    | 2,583 |
| Cash paid for income taxes                                                                     |     | $                |      9 |     | $    |   444 |
| Supplemental non-cash investing and financing                                                  
 activities:                                                                                    |     |                  |        |     |      |       |
| Purchases of property and equipment in accounts payable and accrued expenses and other current 
 liabilities                                                                                    |     | $                |    986 |     | $    | 1,365 |
| Issuance of Series C-1 redeemable convertible preferred                                        
 stock upon settlement of convertible notes                                                     |     | $                | 39,886 |     | $    |     - |
| Deferred offering costs in accounts payable and accrued expenses and other current             
 liabilities                                                                                    |     | $                |      - |     | $    | 1,916 |
| Cash paid for amounts included in the measurement of operating lease liabilities               |     | $                |  4,245 |     | $    | 4,391 |
| Right-of-use                                                                                   
 assets obtained in exchange for new finance lease liabilities                                  |     | $                |    214 |     | $    |     - |
| Operating cash flows from financing leases (interest paid)                                     |     | $                |    140 |     | $    |    68 |

The accompanying notes are an integral part of these interim financial statements. F-43

BILLIONTOONE, INC.

Notes to Unaudited Interim Financial Statements

(1) Description of Business

BillionToOne, Inc. (the
“Company”, “we”, or “our”) was formed in 2016, and headquartered in Menlo Park, California. The Company is a precision diagnostics company that quantifies biology to create molecular diagnostics. The
Company’s proprietary molecular counting platform is designed to detect and measure DNA molecules at the single-count level to help improve disease detection. The Company currently applies the proprietary technology to non-invasive prenatal screening (“Prenatal”) and liquid biopsy (“Oncology”).

(2) Summary of Significant Accounting Policies

Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America
(“U.S. GAAP”). Prior to April 2024, the financial statements also included the Company’s wholly